Sept 10 (Reuters) - Hims & Hers Health ( HIMS ) said on

Wednesday it is launching a new category in men's health,

offering access to personalized treatment plans for low

testosterone.

Hims said it will expand its offerings in the segment in

2026 with the launch of Marius Pharmaceuticals' oral

testosterone Kyzatrex.

Kyzatrex, which received the U.S. Food and Drug

Administration's nod in 2022, has shown to restore testosterone

levels in up to 96% of men, according to Hims.

The telehealth platform said it will also introduce access

to injectable testosterone treatments in 2026.

The company had previously said that it plans to enter the

market for low testosterone and menopause treatments and is

looking at offerings to improve longevity and sleep.

Hims & Hers flourished over the last year when a shortage of

Novo Nordisk's Wegovy and Eli Lilly's ( LLY )

Zepbound allowed them to sell mass quantities of compounded

versions of these weight-loss drugs.